Summit Therapeutics Inc.

What they do

Summit develops ivonescimab, a bispecific antibody combining PD-1 blockade with anti-VEGF effects in a single molecule, which it in-licensed from Akeso Inc. in January 2023. The company holds exclusive development and commercialization rights in North America, South America, Europe, the Middle East, Africa, and Japan, with Akeso retaining China and remaining territories. Its Phase III program covers EGFR-mutated NSCLC after third-generation EGFR TKI therapy (HARMONi), first-line metastatic NSCLC (HARMONi-3), high PD-L1 first-line NSCLC (HARMONi-7), and first-line unresectable metastatic CRC (HARMONi-GI3).

Revenue drivers

• Product revenue — Summit reported $0.00 in annual revenue for 2023 and 2024, and no commercial product is approved; ivonescimab is investigational in Summit's territories.
• Ivonescimab in EGFR-mutated NSCLC (potential first launch) — The BLA for ivonescimab plus chemotherapy in previously treated EGFR-mutated non-squamous NSCLC was accepted for filing by the FDA in January 2026; this is the nearest-term potential revenue source.
• Ivonescimab in first-line NSCLC (HARMONi-3, HARMONi-7) — Two ongoing Phase III first-line NSCLC trials (squamous and non-squamous cohorts, and high PD-L1 monotherapy) represent larger potential indications but are not yet revenue-generating.
• Ivonescimab in colorectal cancer (HARMONi-GI3) — A Phase III first-line unresectable metastatic CRC trial expands the program into a second tumor type; no revenue contribution to date.

Recent performance

Summit reported a net loss of $1,079.6 million for the year ended December 31, 2025, with operating cash use of $322.9 million, and an accumulated deficit of $2,294.2 million at year-end 2025. Annual revenue was $0.00 in both 2023 and 2024. At June 30, 2026, total assets were $752.2 million, total liabilities $122.2 million, shareholder equity $630.0 million, and cash and equivalents $419.4 million; the second-quarter 2026 earnings release cites $690.7 million in cash and investments. The company stated that in May 2025 the HARMONi trial met its primary PFS endpoint with a hazard ratio of 0.52 (95% CI 0.41–0.66; p<0.00001) and median PFS of 6.8 versus 4.4 months, with a positive but not statistically significant OS trend (HR 0.79; 95% CI 0.62–1.01; p=0.057).

Strategy

Summit's stated priority is advancing ivonescimab through late-stage development and toward regulatory approval, starting with the FDA-accepted BLA in previously treated EGFR-mutated non-squamous NSCLC. It is running multiregional Phase III trials in first-line squamous and non-squamous NSCLC, high PD-L1 first-line NSCLC, and first-line metastatic CRC. The company funds operations primarily through equity and debt issuances and license arrangements, and has said it expects to continue incurring operating losses for the foreseeable future while investing in ivonescimab development. It in-licensed ivonescimab from Akeso in January 2023 and expanded its licensed territories via a June 2024 amendment to include Latin America, the Middle East, and Africa.

Risks

• No approved product or revenue — Summit reported $0.00 annual revenue in 2023 and 2024, and ivonescimab remains investigational in its licensed territories, so profitability depends on future approvals.
• Large and growing losses — The company reported a 2025 net loss of $1,079.6 million and an accumulated deficit of $2,294.2 million, and expects operating losses for the foreseeable future.
• Need for additional capital — The 10-K states Summit will need to raise additional capital to fund ongoing operations, and that such financing may not be available on acceptable terms or at all.
• Clinical and regulatory uncertainty — In HARMONi, OS did not reach statistical significance (HR 0.79; 95% CI 0.62–1.01; p=0.057), and the company notes there are currently no FDA-approved regimens demonstrating a statistically significant OS benefit in that setting.

Outlook

Management points to two recent readouts: HARMONi-6, described as the first Phase III head-to-head study showing a statistically significant and clinically meaningful overall survival benefit over an anti-PD-(L)1 antibody-containing regimen in 1L squamous NSCLC, and updated HARMONi overall survival data showing consistent results in Western and Asian patients. For HARMONi-3, the company says final PFS analysis events for the squamous cohort are expected in the second half of 2026 with interim OS analyses planned, and non-squamous cohort PFS events are expected in the first half of 2027. Summit closed the second quarter of 2026 with $690.7 million in cash and investments, and the FDA has accepted for filing its BLA in previously treated EGFR-mutated non-squamous NSCLC.